Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05002569 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,093
- Enrollment target
NCT05002569: Clinical Trial Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT05002569 is a Phase 3 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 1,093 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05002569, a Phase 3 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,093 participants
- Enrollment target
Study Summary
The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
Primary Outcome
RFS is defined as the time between the date of randomization and the first date of documented recurrence (local, regional, distant, new primary melanoma) or death due to any cause, whichever occurs first.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Nivolumab + Relatlimab Fixed Dose Combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,093 participants |
| Start Date | 2021-10-19 |
| Est. Completion | 2025-04-02 |
| Phase | Phase 3 |
Why NCT05002569 stopped before completion
NCT05002569 is an interventional study that assigns participants to a tested intervention. Its 1,093 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% higher).
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT05002569 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05002569 about?
NCT05002569 is a clinical study titled "A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma". The purpose of this study is to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.
What is the current status of trial NCT05002569?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,093 participants. The study started on 2021-10-19. Estimated completion is 2025-04-02.
What interventions are being tested in trial NCT05002569?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Nivolumab + Relatlimab Fixed Dose Combination (BIOLOGICAL).
Who is sponsoring clinical trial NCT05002569?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05002569's enrollment target sits among peer trials
1,093 266th of 2000 higher than 1,735 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03754114 · 1,094 participants · NA
Brain Oxygen Optimization in Severe TBI, Phase 3
- NCT06118983 · 1,094 participants · NA
Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)
- NCT06585241 · 1,094 participants · Phase 4
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
- NCT07196722 · 1,092 participants · Phase 2
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI